Clinical trials: Vaccine
Rabies Post-exposure Prophylaxis
Real World Evidence Study of SYN023 in Children Exposed to Rabies
This observational study is an open-label, prospective, multi-center design. The goal is to evaluate the long-term clinical survival outcomes at 3 months and 1 year in individuals under 18 years of age with WHO Category III…
- Trial name
- NCT07327307
- Where
- 6 sites in China
- Volunteers
- 232 people
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Preventive Immunization COVID-19
An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine Against COVID-19
The purpose of the study is to assess safety, tolerability and immunogenicity of the drug "Gam-COVID-Vac ", a solution for intramuscular administration, with the participation of healthy volunteers Study objectives A safety and…
- Trial name
- NCT04436471
- Testing
- Gam-COVID-Vac
- Where
- Russia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Rabies Vaccination Reaction
The Role of Fatty Acids in Vaccine Efficacy
This study intends to use a randomized controlled trial design to vaccinate all participants against rabies and perform ARA interventions during vaccination to test the efficacy, safety, and intestinal flora of each group after…
- Trial name
- NCT05987384
- Testing
- Arachidonic acid, Sunflower oil, Rabies Vaccine (Vero Cell) for Human Use
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tsinghua University
Recurrent Colon Cancer, Recurrent Gastric Cancer
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating…
- Conditions
- Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer
- Trial name
- NCT01191684
- Testing
- laboratory biomarker analysis, enzyme-linked immunosorbent assay, flow cytometry
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
COVID-19
Improving COVID-19 Vaccine Uptake Among Black and Latino Youth
Black and Latino youth may be less likely to get the COVID-19 vaccine than White youth. In this study we will work with community members to come up with ways to help Black and Latino families learn more about the COVID-19…
- Trial name
- NCT05293392
- Testing
- Culturally-Tailored COVID-19 Vaccine Uptake Intervention, Standard Care
- Where
- United States
- Volunteers
- 5,792 people
- Sponsor
- Nemours Children's Health System
Prevention of Meningococcal Infection
Kinetics of B Cell Response in Infants Menjugate Vaccination
Kinetics of B cell response in infants Menjugate vaccination
- Trial name
- NCT00310700
- Testing
- Meningococcal C conjugate vaccine
- Where
- United Kingdom
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Novartis
Cholera
Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine
Various field studies has found that the modified , bivalent, whole cell - based oral cholera vaccine (OCV) to be safe, immunogenic and effective with protective efficacy of 67 % in earlier clinical trials.
- Trial name
- NCT01508507
- Where
- India
- Volunteers
- 240 people
- Sponsor
- International Vaccine Institute
Influenza
A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults
Recombinant hemagglutinin has been shown to induce protective neutralising antibodies against avian influenza virus but is relatively non-immunogenic.
- Trial name
- FLU003 (NCT02335164)
- Testing
- recombinant influenza hemagglutinin, Advax1, Advax2
- Where
- Australia
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Cancer
Influenza Vaccination in Cancer Patients
The purpose of this study is to determine the timing of influenza vaccination to induce higher antibody response in adult patients with non-hematologic malignancies receiving scheduled cytotoxic chemotherapy.
- Trial name
- NCT02213432
- Testing
- Different timing of influenza vaccination
- Where
- South Korea
- Volunteers
- 97 people
- Sponsor
- Seoul National University Hospital
Infections, Papillomavirus
Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.
This study will collect safety data of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in healthy females of Chinese origin who are unable to receive all three doses of commercially available HPV vaccine before…
- Trial name
- NCT00811798
- Testing
- Cervarix
- Where
- Hong Kong
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines
This study is a randomized, simple-blinded comparative phase III clinical trial comparing the immunogenicity of two doses Coronovac to that of a first dose of Coronovac (Sinovac, Beijing, China) followed by a booster shot with…
- Trial name
- NCT05668065
- Testing
- CoronaVac/CoronaVac, CoronaVac/BNT162b2
- Where
- 5 sites in Tunisia
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur de Tunis
Virus Disease, DNA Virus Infections
The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates
The primary safety objective of this study is to assess the safety of 10 mcg recombinant hepatitis B vaccine in the Chinese health neonates.
- Conditions
- Virus Disease, DNA Virus Infections, Hepadnaviridae Infections
- Trial name
- NCT01183611
- Testing
- Experimental recombinant hepatitis B vaccine, HBIG, Active Comparator hepatitis B vaccine, Experimental recombinant hepatitis B vaccine
- Where
- China
- Volunteers
- 1,740 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza (Healthy Volunteers)
Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older
Primary Objective: To demonstrate the superior relative effectiveness of QIV-HD as compared to QIV-SD among persons 65 years of age and older for the prevention of cardiovascular and/or respiratory hospitalizations.
- Trial name
- NCT04137887
- Testing
- Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD), Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)
- Where
- Finland
- Volunteers
- 33,096 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Covid19
Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above
The aim of the clinical study is to study the safety, reactogenicity and immunogenicity indicators of the EpiVacCorona vaccine, with the involvement of volunteers aged 60 years and above.
- Trial name
- NCT05021016
- Testing
- EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
- Where
- Russia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
Influenza
Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults
To assess the tolerability and safety of a single injection of Influenza VLP Vaccine when administered intramuscularly (IM) at 15 µg and 60 µg HA per each strain.
- Trial name
- NCT01014806
- Testing
- Influenza VLP Vaccine, TIV
- Where
- 6 sites in United States
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- Novavax
Infections, Papillomavirus
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination
The purpose of this post-marketing study is to evaluate the incidence of autoimmune diseases (AIDs) following females who have received at the least the first dose of Cervarix® as part of their routine health care.
- Trial name
- NCT01153906
- Testing
- Data collection
- Where
- United States
- Volunteers
- 1,516 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Project REMOTE (REimagining Measurements and Operations of Translational Endpoints)
This trial is designed to assess immunological biomarkers measured from blood samples that can be used to reliably predict how well vaccines work against symptomatic COVID-19 as well as to evaluate the feasibility of remote…
- Trial name
- REMOTE (NCT06776367)
- Testing
- Remote study participation and self-collection of specimens, Traditional clinical trial participation with clinician-collected specimens
- Where
- 16 sites in United States
- Volunteers
- 1,753 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
Intraocular Melanoma, Malignant Conjunctival Neoplasm
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with GM-CSF, CpG 7909, and incomplete Freund's adjuvant may make a stronger immune…
- Conditions
- Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
- Trial name
- NCT00471471
- Testing
- Peptide vaccine, GM-CSF, PF3512676
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Ahmad Tarhini
Malaria
Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum
This study will evaluate the safety and effectiveness of a vaccine called AMA1-C1/ISA. Malaria is a serious infection of red blood cells caused by a parasite. There are 300 to 500 million malaria cases worldwide each year.
- Trial name
- NCT00487916
- Testing
- AMA1-C1/ISA 720
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist
The purpose of this research is to compare the safety and ability to stimulate antibodies (part of the bodies proteins that fight infections) of two influenza (flu) vaccines given to children 12 to 35 months old.
- Trial name
- NCT00231907
- Testing
- FluMist, Fluzone
- Where
- 3 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)